Gelsemium sempervirens (GS) extract is being used in phytomedicine and homeopathy for its anxiolytic properties but its mechanism of action is yet to be understood. Evidence from rodent models suggests existence of its high sensitivity to the central nervous system even in ultra‑diluted conditions. The diverse effects of its extract and/or its main alkaloids‑gelsemine, sempervirine, and koumine have been shown through different experiments in recent years. Sempervirine intercalates with DNA and inhibits topoisomerase‑I activity, which is thought to be a potential target for restricting viral replication during SARS‑CoV‑2 pathogenesis. Delta SARS‑CoV‑2 spike RBD,
the recombinant protein, was procured from Abclonal Pvt. Ltd. 14th‑day‑old Gallus gallus domesticus embryos were inoculated with RBD protein along with control alcohol in pre‑ and post‑treatment sets and challenged with Gelsemium 6CH, 30CH and 200CH potencies. After 48h, allantoic ϐluids were collected during harvesting and stored at −20 ℃ for the study of different cytokine gene expressions by RT‑PCR (Reverse Transcription Polymerase Chain Reaction). GS at 6CH, 30CH, and 200CH dilutions showed up‑regulation of IFN‑α and IL‑10 gene expressions in all experimental sets. Tendencies of down‑regulation of the genes were seen with TGF‑β1, IL‑1β, and IL‑6 cytokines, with few exceptions. IFN‑β and IL‑1β gene expression changes were relatively mild and mostly inconclusive. All expressions indicate a possible balancing effect between pro‑inϐlammatory and anti‑inϐlammatory cytokine gene expressions by Gelsemium. Ultra‑diluted GS in homeopathic doses can effectively modulate the expression of cytokine genes in SARS‑CoV‑2‑induced cytokine imbalance. Further studies are desired to understand its utility in clinical practice through structured clinical trials.

One of the causes of infertility and recurrent miscarriage is immunological factors or factors related to the immune system. Several immunological issues, for instance autoantibodies and alterations in the level of uterine immune cells, play a crucial role in immune-related infertility. This review evaluated all available immunological bases in female reproductive disorders, especially infertility and miscarriage to provide optimal diagnostic strategies for patients. NK cells are considered important elements of the innate immune system, ensuring that there is tolerance between the mother and child’s immune systems. Touching on the adaptive immune system, Th cells not only are able to impart directional structure on incoming lymphocytes draining from the periphery but also categorize into different subsets depending on where they are located within peripheral blood. During pregnancy, the immune system is skewed toward a type 2 T helper response, while fetal rejection is associated with a type 1 response The rules of organ transplantation require that the host’s immunological mechanisms, based on the incompatibility of antigens of the histocompatibility system, recognize the transplanted piece and ultimately reject it. Among the various therapeutic options, lymphocyte immunotherapy (LIT) stands out as a promising solution based on immunological principles. Some studies have shown that the success rate of LIT is 69%, but other studies have shown that the success rate has increased to 80%. On the other hand, controlled clinical trials are needed to further investigate immunomodulatory therapeutic strategies to help treat this disorder. Therefore, further studies are needed to achieve standardized diagnostic and immunological therapeutic approaches to increase the effectiveness of therapeutic interventions and increase the success rate of assisted reproductive technology (ART) cycles in these women.

The Notch1 signaling pathway is pivotal in neuroimmunomodulation and inflammation, and it significantly contributes to the development and pathogenesis of the nervous system. Consequently, targeting Notch signaling may offer a promising therapeutic approach for neurological disorders. In this investigation, we elucidated the crucial role of Notch1 signaling in neuronal apoptosis, immune regulation, and inflammatory signaling by knocking down the Notch1 gene in mouse hippocampal HT22 cells. Suppression of Notch1 resulted in a marked reduction in the expression of its downstream effector molecule Hes1, accompanied by a significant rise in apoptosis, increased levels of apoptosis-related proteins, and diminished cell viability. RNA sequencing analyses further revealed that differential expression was closely linked to apoptosis, immune-regulatory pathways, and inflammatory signaling. Apoptosis serves as a critical mechanism for eliminating abnormal cells and can impact immune response balance by modulating immune cell activation and function. Notch1 signaling can indirectly affect the neuroimmune microenvironment by regulating neuronal apoptosis. Thus, targeting the Notch1 signaling pathway not only safeguards neuronal function by inhibiting apoptosis but also modulates immune cell activation and inflammatory responses, offering a novel strategy for the immunotherapy of neurodegenerative and cerebrovascular diseases. Comprehending this mechanism provides a crucial foundation for exploring Notch1 immunotherapy for these conditions. By precisely modulating Notch1 signaling, it is anticipated that future therapies can achieve the dual benefits of neuroprotection and immunomodulation, paving the way for innovative treatments for related diseases.

Rheumatoid arthritis (RA) is a systemic autoimmune disorder driven by aberrant cytokine-mediated signalling that perpetuates synovial inflammation and joint destruction. Baricitinib, an oral Janus kinase-1/2 inhibitor, offers a mechanism-based therapeutic option; however, comparative data clarifying its broader immunomodulatory advantages remain limited. We conducted a 24-week, multicentre, double-blind, randomised controlled trial to compare the efficacy and safety of baricitinib with the tumour-necrosis-factor inhibitor adalimumab and with placebo in adults with moderate-to-severe RA who had an inadequate response to conventional synthetic DMARDs. Three hundred participants were allocated equally (1:1:1) to once-daily baricitinib 4 mg, subcutaneous adalimumab 40 mg every other week, or matched placebo, all on stable methotrexate. Co-primary endpoints were (i) mean change from baseline in the Disease Activity Score using 28 joints and C-reactive protein (DAS28-CRP) and (ii) the proportion of patients achieving clinical remission (DAS28-CRP < 2.6) at week 24. Secondary outcomes included the Health Assessment Questionnaire-Disability Index (HAQ-DI), 36-Item Short-Form Survey (SF-36), radiographic progression via modified Total Sharp Score (mTSS), and comprehensive safety assessments. Baricitinib achieved a greater DAS28 reduction (−3.3 ± 0.9) than adalimumab (−2.9 ± 0.8) and placebo (−1.5 ± 0.7), with remission rates of 50%, 45%, and 20%, respectively. Baricitinib also produced superior improvements in HAQ-DI and SF-36 and curtailed radiographic progression versus placebo. Adverse events—predominantly mild upper-respiratory infections—were more frequent with baricitinib, yet serious events were comparable across groups.